Pseudomonas aeruginosa infection in patients with cystic fibrosis: Scientific evidence regarding clinical impact, diagnosis, and treatment;Infecção por pseudomonas aeruginosa em pacientes com fibrose cística: Evidências científicas sobre o impacto clínico, diagnóstico e tratamento

Jornal Brasileiro de Pneumologia

Volumn 39, Issue 4, 2013, Pages 495-512

  Da Silva Filho, Luiz Vicente Ribeiro Ferreira ^a   Ferreira, Flavia de Aguiar ^b   Reis, Francisco José Caldeira ^c   De Britto, Murilo Carlos Amorim ^d   Levy, Carlos Emilio ^e   Clark, Otavio ^f   Ribeiro, José Dirceu ^e  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Novartis Brasil Medical Affairs   (Brazil)

^c Grupo Brasileiro de Estudos em Fibrose Cística   (Brazil)

^d INSTITUTO DE MEDICINA INTEGRAL PROF FERNANDO FIGUEIRA   (Brazil)

^e UNIVERSITY OF CAMPINAS   (Brazil)

^f Evidências Consultoria   (Brazil)

Author keywords

Cystic fibrosis diagnosis; Cystic fibrosis drug therapy; Evidence based medicine; Pseudomonas aeruginosa

Indexed keywords

CYSTIC FIBROSIS; EVIDENCE BASED MEDICINE; HUMAN; MICROBIOLOGY; PROGNOSIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; REVIEW;

CYSTIC FIBROSIS; EVIDENCE-BASED MEDICINE; HUMANS; PROGNOSIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84884733385     PISSN: 18063713     EISSN: 18063756     Source Type: Journal    
DOI: 10.1590/s1806-37132013000400015     Document Type: Review

References (104)

1. Ratjen F, Döring G. Cystic fibrosis. Lancet. 2003;361(9358):681-9. http://dx.doi.org/10.1016/S0140-6736(03)12567-6
2. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ Jr, Willey-Courand DB, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007;176(10):957-69. http://dx.doi.org/10.1164/rccm.200705-664OC PMid:17761616
3. Ratjen FA. Cystic fibrosis: pathogenesis and future treatment strategies. Respir Care. 2009;54(5):595-605. http://dx.doi.org/10.4187/aarc0427 PMid:19393104
4. Lommatzsch ST, Aris R. Genetics of cystic fibrosis. Semin Respir Crit Care Med. 2009;30(5):531-8. http://dx.doi.org/10.1055/s-0029-1238911 PMid:19760540
5. Ratjen F. Diagnosing and managing infection in CF. Paediatr Respir Rev. 2006;7 Suppl 1:S151-3. http://dx.doi.org/10.1016/j.prrv.2006.04.217 PMid:16798546
6. Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev. 1996;60(3):539-74. PMid:8840786 PMCid:239456
7. Li Z, Kosorok MR, Farrell PM, Laxova A, West SE, Green CG, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA. 2005;293(5):581-8. http://dx.doi.org/10.1001/jama.293.5.581 PMid:15687313
8. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168(8):918-51. http://dx.doi.org/10.1164/rccm.200304-505SO PMid:14555458
9. Deschaght P, Van Daele S, De Baets F, Vaneechoutte M. PCR and the detection of Pseudomonas aeruginosa in respiratory samples of CF patients. A literature review. J Cyst Fibros. 2011;10(5):293-7. http://dx.doi.org/10.1016/j.jcf.2011.05.004 PMid:21684819
10. Nixon GM, Armstrong DS, Carzino R, Carlin JB, Olinsky A, Robertson CF, et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr. 2001;138(5):699-704. http://dx.doi.org/10.1067/mpd.2001.112897 PMid:11343046
11. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol. 1992;12(3):158-61. http://dx.doi.org/10.1002/ppul.1950120306 PMid:1641272
12. Taccetti G, Campana S, Festini F, Mascherini M, Döring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J. 2005;26(3):458-61. http://dx.doi.org/10.1183/09031936.05.00009605 PMid:16135728
13. CEBM Centre For Evidence Based Medicine [homepage on the Internet]. Oxford: University of Oxford. [cited 2013 Feb 11]. The Oxford 2011 Levels of Evidence. Available from: http://www.cebm.net/index.aspx?o=5653
14. Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros. 2003;2(1):29-34. http://dx.doi.org/10.1016/S1569-1993(02)00141-8
15. Corey M. Survival estimates in cystic fibrosis: snapshots of a moving target. Pediatr Pulmonol. 1996;21(3):149-50. http://dx.doi.org/10.1002/1099-0496(199603)21:3149::AID-PPUL19502103023.0.CO;2-C
16. Hudson VL, Wielinski CL, Regelmann WE. Prognostic implications of initial oropharyngeal bacterial flora in patients with cystic fibrosis diagnosed before the age of two years. J Pediatr. 1993;122(6):854-60. http://dx.doi.org/10.1016/S0022-3476(09)90007-5
17. Kosorok MR, Zeng L, West SE, Rock MJ, Splaingard ML, Laxova A, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol. 2001;32(4):277-87. http://dx.doi.org/10.1002/ppul.2009.abs PMid:11568988
18. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002;34(2):91-100. http://dx.doi.org/10.1002/ppul.10127 PMid:12112774
19. Lebecque P, Leal T, Zylberberg K, Reychler G, Bossuyt X, Godding V. Towards zero prevalence of chronic Pseudomonas aeruginosa infection in children with cystic fibrosis. J Cyst Fibros. 2006;5(4):237-44. http://dx.doi.org/10.1016/j.jcf.2006.04.001 PMid:16790367
20. Ratjen F. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis. Curr Opin Pulm Med. 2006;12(6):428-32. http://dx.doi.org/10.1097/01.mcp.0000245712.51514.a1 PMid:17053493
21. Equi AC, Pike SE, Davies J, Bush A. Use of cough swabs in a cystic fibrosis clinic. Arch Dis Child. 2001;85(5):438-9. http://dx.doi.org/10.1136/adc.85.5.438 PMid:11668115 PMCid:1718986
22. da Silva Filho LV, Tateno AF, Martins KM, Azzuz Chernishev AC, Garcia Dde O, Haug M, et al. The combination of PCR and serology increases the diagnosis of Pseudomonas aeruginosa colonization/infection in cystic fibrosis. Pediatr Pulmonol. 2007;42(10):938-44. http://dx.doi.org/10.1002/ppul.20686 PMid:17722007
23. Hoiby N, Flensborg EW, Beck B, Friis B, Jacobsen SV, Jacobsen L. Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. Scand J Respir Dis. 1977;58(2):65-79. PMid:404701
24. Brett MM, Ghoneim AT, Littlewood JM. Prediction and diagnosis of early Pseudomonas aeruginosa infection in cystic fibrosis: a follow-up study. J Clin Microbiol. 1988;26(8):1565-70. Erratum in: J Clin Microbiol 1989;27(1):230. PMid:3139707 PMCid:266661
25. West SE, Zeng L, Lee BL, Kosorok MR, Laxova A, Rock MJ, et al. Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors. JAMA. 2002;287(22):2958-67. http://dx.doi.org/10.1001/jama.287.22.2958 PMid:12052125
26. Kappler M, Kraxner A, Reinhardt D, Ganster B, Griese M, Lang T. Diagnostic and prognostic value of serum antibodies against Pseudomonas aeruginosa in cystic fibrosis. Thorax. 2006;61(8):684-8. http://dx.doi.org/10.1136/thx.2005.049536 PMid:16449259 PMCid:2104684
27. Tramper-Stranders GA, van der Ent CK, Slieker MG, Terheggen-Lagro SW, Teding van Berkhout F, Kimpen JL, et al. Diagnostic value of serological tests against Pseudomonas aeruginosa in a large cystic fibrosis population. Thorax. 2006;61(8):689-93. http://dx.doi.org/10.1136/thx.2005.054726 PMid:16601093 PMCid:2104678
28. Ratjen F, Walter H, Haug M, Meisner C, Grasemann H, Döring G. Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients. Pediatr Pulmonol. 2007;42(3):249-55. http://dx.doi.org/10.1002/ppul.20562 PMid:17243185
29. Weisner AM, Chart H, Bush A, Davies JC, Pitt TL. Detection of antibodies to Pseudomonas aeruginosa in serum and oral fluid from patients with cystic fibrosis. J Med Microbiol. 2007;56(Pt 5):670-4. http://dx.doi.org/10.1099/jmm.0.46833-0 PMid:17446292
30. Pressler T, Karpati F, Granström M, Knudsen PK, Lindblad A, Hjelte L, et al. Diagnostic significance of measurements of specific IgG antibodies to Pseudomonas aeruginosa by three different serological methods. J Cyst Fibros. 2009;8(1):37-42. http://dx.doi.org/10.1016/j.jcf.2008.08.002 PMid:18835753
31. Milagres LG, Castro TL, Garcia D, Cruz AC, Higa L, Folescu T, et al. Antibody response to Pseudomonas aeruginosa in children with cystic fibrosis. Pediatr Pulmonol. 2009;44(4):392-401. http://dx.doi.org/10.1002/ppul.21022 PMid:19283764
32. Hayes D Jr, Farrell PM, Li Z, West SE. Pseudomonas aeruginosa serological analysis in young children with cystic fibrosis diagnosed through newborn screening. Pediatr Pulmonol. 2010;45(1):55-61. http://dx.doi.org/10.1002/ppul.21083 PMid:20025049 PMCid:2924665
33. Douglas TA, Brennan S, Berry L, Winfield K, Wainwright CE, Grimwood K, et al. Value of serology in predicting Pseudomonas aeruginosa infection in young children with cystic fibrosis. Thorax. 2010;65(11):985-90. http://dx.doi.org/10.1136/thx.2009.132845 PMid:20889526
34. Wainwright CE, Vidmar S, Armstrong DS, Byrnes CA, Carlin JB, Cheney J, et al. Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial. JAMA. 2011;306(2):163-71. http://dx.doi.org/10.1001/jama.2011.954 PMid:21750293
35. Littlewood JM, Miller MG, Ghoneim AT, Ramsden CH. Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis. Lancet. 1985;1(8433):865. http://dx.doi.org/10.1016/S0140-6736(85)92222-6
36. Valerius NH, Koch C, Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet. 1991;338(8769):725-6. http://dx.doi.org/10.1016/0140-6736(91)91446-2
37. Munck A, Bonacorsi S, Mariani-Kurkdjian P, Lebourgeois M, Gérardin M, Brahimi N, et al. Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization. Pediatr Pulmonol. 2001;32(4):288-92. http://dx.doi.org/10.1002/ppul.1121 PMid:11568989
38. Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med. 2003;167(6):841-9. http://dx.doi.org/10.1164/rccm.200208-855OC PMid:12480612
39. Davidson AG, Chilvers MA, Lillquist YP. Effects of a Pseudomonas aeruginosa eradication policy in a cystic fibrosis clinic. Curr Opin Pulm Med. 2012;18(6):615-21. http://dx.doi.org/10.1097/MCP.0b013e328358f5a2 PMid:22990661
40. Ratjen F, Munck A, Kho P, Angyalosi G; ELITE Study Group. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax. 2010;65(4):286-91. http://dx.doi.org/10.1136/thx.2009.121657 PMid:19996339
41. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med. 2011;165(9):847-56. http://dx.doi.org/10.1001/archpediatrics.2011.136 PMid:21893650
42. Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev. 2009;(4):CD004197. PMid:19821321
43. Collaco JM, Green DM, Cutting GR, Naughton KM, Mogayzel PJ Jr. Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes. Am J Respir Crit Care Med. 2010;182(9):1137-43. http://dx.doi.org/10.1164/rccm.201001-0057OC PMid:20581166 PMCid:3001256
44. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994;331(10):637-42. http://dx.doi.org/10.1056/NEJM199409083311003 PMid:7503821
45. Rosenfeld M, Emerson J, Williams-Warren J, Pepe M, Smith A, Montgomery AB, et al. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr. 2001;139(3):359-65. http://dx.doi.org/10.1067/mpd.2001.117288 PMid:11562614
46. Dakin C, Henry RL, Field P, Morton J. Defining an exacerbation of pulmonary disease in cystic fibrosis. Pediatr Pulmonol. 2001;31(6):436-42. http://dx.doi.org/10.1002/ppul.1072 PMid:11389576
47. Flume PA, Mogayzel PJ Jr, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009;180(9):802-8. http://dx.doi.org/10.1164/rccm.200812-1845PP PMid:19729669
48. Stenbit AE, Flume PA. Pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med. 2011;17(6):442-7. PMid:21881509
49. Bilton D, Canny G, Conway S, Dumcius S, Hjelte L, Proesmans M, et al. Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials. J Cyst Fibros. 2011;10 Suppl 2:S79-81. http://dx.doi.org/10.1016/S1569-1993(11)60012-X
50. Balaguer A, González de Dios J. Home versus hospital intravenous antibiotic therapy for cystic fibrosis. Cochrane Database Syst Rev. 2012;3:CD001917. PMid:22419283
51. Smyth A, Elborn JS. Exacerbations in cystic fibrosis: 3. Management. Thorax. 2008;63(2):180-4. http://dx.doi.org/10.1136/thx.2006.060905 PMid:18234661
52. Smyth A, Knox A. Twice vs three times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis. J Cyst Fibros. 2011;10(5):383. http://dx.doi.org/10.1016/j.jcf.2011.03.010 PMid:21507733
53. Breidenstein EB, de la Fuente-Nú-ez C, Hancock RE. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol. 2011;19(8):419-26. http://dx.doi.org/10.1016/j.tim.2011.04.005 PMid:21664819
54. Cheng K, Smyth RL, Govan JR, Doherty C, Winstanley C, Denning N, et al. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet. 1996;348(9028):639-42. http://dx.doi.org/10.1016/S0140-6736(96)05169-0
55. Elphick HE, Tan A. Single versus combination intravenous antibiotic therapy for people with cystic fibrosis. Cochrane Database Syst Rev. 2005;(2):CD002007. PMid:15846627
56. Bosso JA, Saxon BA, Matsen JM. Comparative activity of cefepime, alone and in combination, against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients. Antimicrob Agents Chemother. 1991;35(4):783-4. http://dx.doi.org/10.1128/AAC.35.4.783 PMid:1906264 PMCid:245101
57. Tré-Hardy M, Nagant C, El Manssouri N, Vanderbist F, Traore H, Vaneechoutte M, et al. Efficacy of the combination of tobramycin and a macrolide in an in vitro Pseudomonas aeruginosa mature biofilm model. Antimicrob Agents Chemother. 2010;54(10):4409-15. http://dx.doi.org/10.1128/AAC.00372-10 PMid:20696878 PMCid:2944582
58. Leroy A, Humbert G, Oksenhendler G, Fillastre JP. Pharmacokinetics of aminoglycosides in subjects with normal and impaired renal function. Antibiot Chemother. 1978;25:163-80. PMid:352252
59. Kovarik JM, Hoepelman IM, Verhoef J. Once-daily aminoglycoside administration: new strategies for an old drug. Eur J Clin Microbiol Infect Dis. 1989;8(9):761-9. http://dx.doi.org/10.1007/BF02185842 PMid:2512146
60. Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother. 1997;39(6):677-86. http://dx.doi.org/10.1093/jac/39.6.677 PMid:9222035
61. Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, Ioannidis JP. Extended-interval aminoglycoside administration for children: a meta-analysis. Pediatrics. 2004;114(1):e111-8. http://dx.doi.org/10.1542/peds.114.1.e111 PMid:15231982
62. Smyth AR, Bhatt J. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev. 2012;2:CD002009. PMid:22336782
63. Plummer A, Wildman M. Duration of intravenous antibiotic therapy in people with cystic fibrosis. Cochrane Database Syst Rev. 2011;(1):CD006682. PMid:21249681
64. VanDevanter DR, O'Riordan MA, Blumer JL, Konstan MW. Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations. Respir Res. 2010;11:137. http://dx.doi.org/10.1186/1465-9921-11-137 PMid:20925941 PMCid:2959026
65. Hodson ME, Penketh AR, Batten JC. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet. 1981;2(8256):1137-9. http://dx.doi.org/10.1016/S0140-6736(81)90588-2
66. Szaff M, Høiby N, Flensborg EW. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand. 1983;72(5):651-7. http://dx.doi.org/10.1111/j.1651-2227.1983.tb09789.x PMid:6637463
67. Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Kravitz RM, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med. 1993;328(24):1740-6. http://dx.doi.org/10.1056/NEJM199306173282403 PMid:8497284
68. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999;340(1):23-30. http://dx.doi.org/10.1056/NEJM199901073400104 PMid:9878641
69. MacLusky IB, Gold R, Corey M, Levison H. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol. 1989;7(1):42-8. http://dx.doi.org/10.1002/ppul.1950070110 PMid:2505216
70. Murphy TD, Anbar RD, Lester LA, Nasr SZ, Nickerson B, VanDevanter DR, et al. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr Pulmonol. 2004;38(4):314-20. http://dx.doi.org/10.1002/ppul.20097 PMid:15334509
71. Cystic Fibrosis Trust [homepage on the Internet]. Bromley: Cystic Fibrosis Trust. [cited 2013 Feb 11]. Antibiotic treatment for cystic fibrosis 2009. [Adobe Acrobat document, 102p.]. Available from: https://www.cysticfibrosis.org.uk/media/82010/CD_Antibiotic_treatment_for_CF_May_09.pdf
72. Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J. 2002;20(3):658-64. http://dx.doi.org/10.1183/09031936.02.00248102 PMid:12358344
73. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med. 2008;178(9):921-8. http://dx.doi.org/10.1164/rccm.200712-1804OC PMid:18658109 PMCid:2577727
74. Oermann CM, Retsch-Bogart GZ, Quittner AL, Gibson RL, McCoy KS, Montgomery AB, et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol. 2010;45(11):1121-34. http://dx.doi.org/10.1002/ppul.21301 PMid:20672296
75. Konstan MW, Flume PA, Kappler M, Chiron R, Higgins M, Brockhaus F, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros. 2011;10(1):54-61. http://dx.doi.org/10.1016/j.jcf.2010.10.003 PMid:21075062
76. Geller DE, Flume PA, Staab D, Fischer R, Loutit JS, Conrad DJ, et al. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2011;183(11):1510-6. http://dx.doi.org/10.1164/rccm.201008-1293OC PMid:21471106
77. Ryan G, Singh M, Dwan K. Inhaled antibiotics for long-term therapy in cystic fibrosis. Cochrane Database Syst Rev. 2011;(3):CD001021. PMid:21412868
78. Sawicki GS, Tiddens H. Managing treatment complexity in cystic fibrosis: challenges and opportunities. Pediatr Pulmonol. 2012;47(6):523-33. http://dx.doi.org/10.1002/ppul.22546 PMid:22467341
79. Robinson P. Cystic fibrosis. Thorax. 2001;56(3):237-41. http://dx.doi.org/10.1136/thorax.56.3.237 PMid:11182019 PMCid:1758774
80. Bell SC, Robinson PJ. Exacerbations in cystic fibrosis: 2. prevention. Thorax. 2007;62(8):723-32. http://dx.doi.org/10.1136/thx.2006.060897 PMid:17687099 PMCid:2117269
81. Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros. 2009;8(2):91-6. http://dx.doi.org/10.1016/j.jcf.2008.09.007 PMid:18952504 PMCid:2680350
82. Milgrom H, Bender B, Ackerson L, Bowry P, Smith B, Rand C. Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol. 1996;98(6 Pt 1):1051-7. http://dx.doi.org/10.1016/S0091-6749(96)80190-4
83. Ievers CE, Brown RT, Drotar D, Caplan D, Pishevar BS, Lambert RG. Knowledge of physician prescriptions and adherence to treatment among children with cystic fibrosis and their mothers. J Dev Behav Pediatr. 1999;20(5):335-43. http://dx.doi.org/10.1097/00004703-199910000-00008 PMid:10533992
84. Rau JL. Determinants of patient adherence to an aerosol regimen. Respir Care. 2005;50(10):1346-56; discussion 1357-9. PMid:16185370
85. DiGirolamo AM, Quittner AL, Ackerman V, Stevens J. Identification and assessment of ongoing stressors in adolescents with a chronic illness: an application of the behavior-analytic model. J Clin Child Psychol. 1997;26(1):53-66. http://dx.doi.org/10.1207/s15374424jccp2601_6 PMid:9118176
86. Gudas LJ, Koocher GP, Wypij D. Perceptions of medical compliance in children and adolescents with cystic fibrosis. J Dev Behav Pediatr. 1991;12(4):236-42. http://dx.doi.org/10.1097/00004703-199108000-00004 PMid:1939678
87. Modi AC, Quittner AL. Barriers to treatment adherence for children with cystic fibrosis and asthma: what gets in the way? J Pediatr Psychol. 2006;31(8):846-58. http://dx.doi.org/10.1093/jpepsy/jsj096 PMid:16401680
88. Dalcin Pde T, Rampon G, Pasin LR, Ramon GM, Abrahão CL, Oliveira VZ. Adherence to treatment in patients with cystic fibrosis. J Bras Pneumol. 2007;33(6):663-70. PMid:18200366
89. Eakin MN, Bilderback A, Boyle MP, Mogayzel PJ, Riekert KA. Longitudinal association between medication adherence and lung health in people with cystic fibrosis. J Cyst Fibros. 2011;10(4):258-64. http://dx.doi.org/10.1016/j.jcf.2011.03.005 PMid:21458391 PMCid:3114200
90. Briesacher BA, Quittner AL, Saiman L, Sacco P, Fouayzi H, Quittell LM. Adherence with tobramycin inhaled solution and health care utilization. BMC Pulm Med. 2011;11:5. http://dx.doi.org/10.1186/1471-2466-11-5 PMid:21251275 PMCid:3033861
91. Shinkai M, Rubin BK. Macrolides and airway inflammation in children. Paediatr Respir Rev. 2005;6(3):227-35. http://dx.doi.org/10.1016/j.prrv.2005.06.005 PMid:16153572
92. Kudoh S, Uetake T, Hagiwara K, Hirayama M, Hus LH, Kimura H, et al. Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis [Article in Japanese]. Nihon Kyobu Shikkan Gakkai Zasshi. 1987;25(6):632-42. PMid:3682440
93. McArdle JR, Talwalkar JS. Macrolides in cystic fibrosis. Clin Chest Med. 2007;28(2):347-60. http://dx.doi.org/10.1016/j.ccm.2007.02.005 PMid:17467553
94. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet. 2002;360(9338):978-84. http://dx.doi.org/10.1016/S0140-6736(02)11081-6
95. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290(13):1749-56. http://dx.doi.org/10.1001/jama.290.13.1749 PMid:14519709
96. Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2010;303(17):1707-15. http://dx.doi.org/10.1001/jama.2010.563 PMid:20442386
97. Cai Y, Chai D, Wang R, Bai N, Liang BB, Liu Y. Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review. J Antimicrob Chemother. 2011;66(5):968-78. http://dx.doi.org/10.1093/jac/dkr040 PMid:21393178
98. Southern KW, Barker PM, Solis-Moya A, Patel L. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev. 2011;(12):CD002203. PMid:22161368
99. Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest. 2003;123(5):1495-502. http://dx.doi.org/10.1378/chest.123.5.1495 PMid:12740266
100. Aaron SD, Vandemheen KL, Ferris W, Fergusson D, Tullis E, Haase D, et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet. 2005;366(9484):463-71. http://dx.doi.org/10.1016/S0140-6736(05)67060-2
101. Cantón R, Cobos N, de Gracia J, Baquero F, Honorato J, Gartner S, et al. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin Microbiol Infect. 2005;11(9):690-703. http://dx.doi.org/10.1111/j.1469-0691.2005.01217.x PMid:16104983
102. Saiman L, Mehar F, Niu WW, Neu HC, Shaw KJ, Miller G, et al. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis. 1996;23(3):532-7. http://dx.doi.org/10.1093/clinids/23.3.532 PMid:8879776
103. Merlo CA, Boyle MP, Diener-West M, Marshall BC, Goss CH, Lechtzin N. Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis. Chest. 2007;132(2):562-8. http://dx.doi.org/10.1378/chest.06-2888 PMid:17646236
104. Lechtzin N, John M, Irizarry R, Merlo C, Diette GB, Boyle MP. Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration. 2006;73(1):27-33. http://dx.doi.org/10.1159/000087686 PMid:16113513